Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Faldaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 1.00 |
| ▸ | PPP3CB | P16298 | 1/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Faldaprevir SCHEMBL7736941 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL19246297 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL15462595 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL13556415 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL222429 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL24058604 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL227410 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL31554839 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL7736946 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL11947501 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSB 4535/4885PPP3CB 2845/4885ABCC1 4123/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | CTSB 3062/4885PPP3CB 2273/4885ABCC1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.